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Lhx2Generating engraftable hematopoietic stem cells (HSCs) from pluripotent stem cells (PSCs) is an ideal approach
for obtaining induced HSCs for cell therapy. However, the path from PSCs to robustly induced HSCs (iHSCs)
in vitro remains elusive. We hypothesize that the modiﬁcation of hematopoietic niche cells by transcription
factors facilitates the derivation of induced HSCs from PSCs. The Lhx2 transcription factor is expressed in fetal
liver stromal cells but not in fetal blood cells. Knocking out Lhx2 leads to a fetal hematopoietic defect in a
cell non-autonomous role. In this study, we demonstrate that the ectopic expression of Lhx2 in OP9 cells (OP9-
Lhx2) accelerates the hematopoietic differentiation of PSCs. OP9-Lhx2 signiﬁcantly increased the yields of hema-
topoietic progenitor cells via co-culture with PSCs in vitro. Interestingly, the co-injection of OP9-Lhx2 and PSCs
into immune deﬁcient mice also increased the proportion of hematopoietic progenitors via the formation of
teratomas. The transplantation of phenotypic HSCs from OP9-Lhx2 teratomas but not from the OP9 control sup-
ported a transient repopulating capability. The upregulation of Apln gene by Lhx2 is correlated to the hematopoi-
etic commitment property of OP9-Lhx2. Furthermore, the enforced expression of Apln in OP9 cells signiﬁcantly
increased the hematopoietic differentiation of PSCs. These results indicate that OP9-Lhx2 is a good cell line for
regeneration of hematopoietic progenitors both in vitro and in vivo.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Induced hematopoietic stem cells (iHSCs) derived from either plu-
ripotent stem cells (PSCs) or somatic cells are essential to cell therapy
based on HSC transplantation. However, the derivation of iHSCs with
physiologic functions after engraftment has remained a signiﬁcant chal-
lenge (Slukvin, 2013). Several bottlenecks, including the key conditions
of hematopoietic speciﬁcation, maturation, maintenance, and expan-
sion, must be addressed (Shepard and Talib, 2014). The ectopicand/or assembly of data, data
.T.J., X.C.X., L.X.F., M.M.H., D.J.
.K. and P.G.J.: conception and
terpretation, ﬁnancial support,
ience Park, Guangzhou, China,
. This is an open access article underexpression of intrinsic regulatory factors has been hypothesized to di-
rectly convert somatic cell types to hematopoietic stem cells. As a result,
HSC-like cells have been obtained via the conversion of pro-B (Riddell
et al., 2014) and PSC-derived hematopoietic progenitors (Doulatov
et al., 2013). In addition to some defects, these iHSCs may constitute a
tumorigenic risk due to the enforced expression of factors via lenti- or
retro-viral transduction approaches.
To date, the in vitro niche modeling of hematopoietic development
has failed to yield functional HSCs from PSCs (Kennedy et al., 2012), in-
dicating that current extrinsic niche factors are not sufﬁcient for theder-
ivation of iHSCs from PSCs in vitro without the direct combination of
manipulating intrinsic factors. Recently, iHSCs were identiﬁed to result
from intra-teratoma hematopoiesis with low efﬁciency (Amabile et al.,
2013; Suzuki et al., 2013). The efﬁciency of iHSCs derived from terato-
mas was further increased by combining the OP9- and OP9-derived-
cell lines aswell as hematopoietic cytokines. Thus, teratomahematopoi-
esis constitutes a new 3-D in vivo model for studying niche factors for
the derivation of iHSCs from PSCs.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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brain, and deﬁnitive erythrocyte development. Knocking out Lhx2 leads
to severe anemia in a cell non-autonomousmanner (Porter et al., 1997).
The enforced expression of Lhx2 in hematopoietic progenitors from
either PSCs (Pinto do et al., 1998) or adult mouse bone marrow (Pinto
do et al., 2002) results in SCF-dependent cell lines via a cell non-
autonomous mechanism (Pinto do et al., 2001). PSCs that overexpress
Lhx2 can produce HSC-like cells via OP9/PSCs co-culture; however, the
related mechanism remains elusive (Kitajima et al., 2011). In addition
to Lhx2, multiple transcription factors, including Fos, Tcfec, Hmgb1,
and Sfpi1, can enhance the repopulating activity of HSCs in a cell non-
autonomous manner (Deneault et al., 2009). We hypothesize that cer-
tain transcription factors can enhance the hematopoietic speciﬁcation
of PSCs in a cell non-autonomous manner. We report for the ﬁrst time
that the enforced expression of Lhx2 in OP9 stromal cells promotes
the production of hematopoietic progenitors both in vitro and in vivo.
OP9-Lhx2 facilitates hematopoietic speciﬁcation partially via the upreg-
ulation of the Apln gene. Thus, the OP9-Lhx2 cell line can bewidely used
for hematopoietic derivation from PSCs, both in vitro and in vivo.
2. Materials and methods
2.1. Mice
C57BL/6 (B6) mice and NOD/SCID mice were purchased from
Vital River Laboratories (Beijing, China) and housed in the speciﬁc-
pathogen-free (SPF)-grade experimental animal center of Guangzhou
Institutes of Biomedicine and Health (GIBH). All experiments were
conducted with the ethical approval of the Animal Ethics Committee
of GIBH.
2.2. Cell lines and culture condition
OP9 cells weremaintained inα-MEMmedium (Gibco) supplement-
ed with 20% fetal bovine serum (Gibco). hPSCs (National Institutes of
Health code: WA01) were maintained in the feeder-free culture medi-
um mTeSR™1 (Stemcell Technologies). OP9 cells and hPSCs were
co-cultured in differentiation medium consisting of α-MEM medium
supplemented with 10% deﬁned fetal bovine serum (Hyclone) and
monothioglycerol (100 μmol/L).
2.3. In vitro hematopoietic differentiation of hPSCs through stromal cell
co-culture
OP9-GFP/OP9-Lhx2/OP9-Apln cells (8–10 × 105) were plated in
100 mm dishes. When the OP9 cells reached conﬂuence, hPSCs were
plated onto the related stromal cell layer (4–6 × 106 ES cells/dish) and
cultured with differentiation medium. On day 9, CD34+ cells were
enriched using immunomagnetic beads and re-plated to a new dish
containing conﬂuent OP9 cells. BMP4 (20 ng/ml), SCF (50 ng/ml),
TPO (20 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml), and Flt3-L cytokines
(50 ng/ml) were added to the culture. Half of the differentiation
medium was replaced every other day. On day 18, the cells were
collected and analyzed by ﬂow cytometry.
2.4. Teratoma formation and single cell preparation
Formouse teratoma formation, 1 × 106mPSCs and 1× 106 OP9-GFP/
OP9-Lhx2 cells were mixed with Matrigel and co-injected into the
inguen of NOD/SCIDmice (6–8weeks old). For human teratoma forma-
tion, 4 × 106 hPSCs and 1 × 106 OP9-GFP/OP9-Lhx2 cells were mixed
with Matrigel and co-injected into the inguen of NOD/SCID mice (6–8
weeks old). Single teratoma cells were prepared as described with
minor modiﬁcation (Amabile et al., 2013). Brieﬂy, teratomas were
minced into small pieces and dissociatedwith the gentleMACS™ system
(Miltenyi Biotec). The dissociated cells were further digested in 0.2%collagenase IV (Gibco) and 60 U/ml DNAse (Wako Pure Chemical Indus-
tries, Osaka, Japan) at 37 °C for 40 min. The cells were then successively
ﬁltered through 70 μmand 30 μmstrainers. Dead cellswere depleted via
low-speed centrifugation (100 g, 10min, 4 °C) in ammonium-chloride-
potassium lysing buffer. The single live cells were then resuspended in
2% FBS for further phenotypic and functional analyses.
2.5. Flow cytometry analysis and cell sorting
Human antibodies were purchased from BD Biosciences, and mouse
antibodies were purchased from eBioscience. The following antibodies
were added for human blood cell analysis: FITC-conjugated anti-
mCD45 (30-F11), FITC-conjugated anti-mTER-119 (TER-119), PE-Cy7-
conjugated anti-humanCD45, APC-conjugated anti-humanCD34, and
APC-Cy7-conjugated anti-humanCD38. The following antibodies were
added for mouse blood cell analysis: APC-Cy7-conjugated anti-
mCD45.1 and anti-mTER-119, PE-conjugated anti-mCD45.2 (104),
APC-conjugated anti-mCD150 (TC15-12F12.2), and PE-Cy7-conjugated
anti-mCD48 (HM48-1). The following antibodies were added to
analyze the lineage of cells engrafted in the recipients: FITC-
conjugated anti-mCD45.1, PE-conjugated anti-mCD45.2 (104), APC-
conjugated anti-mB220, APC-cy7-conjugated mCD11b (M1/70), and
PE-Cy7-conjugated anti-mCD3e (500A2). After washing, the cells were
stained with 2 μg/ml DAPI in 10% FBS. The cells were analyzed or sorted
on a BD LSRFortessa™ MoFlo Astrios (Beckman Coulter) and BD
FACSAria™ II sorter (BD Bioscences) at the ﬂow cytometry core facility
of the instrument center of GIBH.
2.6. Colony-forming assay
Hematopoietic progenitors derived from either in vitro co-culture or
in vivo teratoma formationwere suspended in 3.3ml ofmethylcellulose
medium (MethoCult H4434, Stem Cell Technologies) and plated in trip-
licate in 35mmdishes at 37 °C in a humidiﬁed atmosphere of 5% CO2 for
10–14 days. Colonies of more than 50 cells were scored as positive
clones.
2.7. RNA-seq
Two micrograms of RNA from the OP9-Lhx2 or OP9-GFP control
sample was used to create libraries for deep sequencing according to
the manual of the TruSeq RNA Sample Preparation Kit (Illumia). The
samples were sequenced using the Illumina Myseq sequencer.
Sequence reads were processed and analyzed by the bioinformatics
core of GIBH.
2.8. Statistical analysis
All quantitative analyses were based on a minimum of three
replicates. Data are presented as means ± SDs. Student's t tests were
performed using the statistic software GraphPad Prism (GraphPad
Software).
3. Results
3.1. OP9-Lhx2/PSCs co-culture enhances the production of hematopoietic
progenitor cells
To generate a OP9-Lhx2 cell line that stably overexpressed mouse
Lhx2, Lhx2 cDNA (OriGene) was subcloned into pMYs-IRES-EGFP
(RTV-021, Cell Biolabs, INC) to generate the pMYs-Lhx2-IRES-EGFP vec-
tor. OP9 cells were transduced with Lhx2 or GFP retrovirus packaged
using plat-E cells via calcium phosphate-mediated transfection as de-
scribed previously (Yang et al., 2015). As shown in Fig. S1A, the GFP+
OP9 cells reached 100% after two rounds of viral transduction. To con-
ﬁrm the ectopic expression of Lhx2, we ﬁrst carried out quantitative
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higher in OP9-Lhx2 than in OP9 cells transduced with the GFP control
(Fig. S1B).We conducted awestern blot assay using anti-Lhx2monoclo-
nal antibody to further conﬁrm the expression level of Lhx2 at the pro-
tein level (N-20, Santa Cruz Biotech). A 55 kDa band was speciﬁcally
detected in the OP9-Lhx2 sample but was absent in the OP9 control
sample (Fig. S1C). The overexpression of Lhx2 in mouse bone marrow
cells produced SCF-dependent cell lines (Pinto do et al., 2002), which
is a feature of Lhx2 function. To functionally conﬁrm Lhx2 expression,
we also cultured Lhx2-transducedmouse bonemarrow cells inmedium
containing mSCF. As expected, the ectopic expression of Lhx2 in mouse
bone marrow allowed the cells to replicate indeﬁnitely in the presenceFig. 1. OP9-Lhx2 enhances generation of ESCs-derived hematopoietic cells. (A) Strategy for hem
ﬁcation of hematopoietic cells by FACS analysis. Dead cells anddebriswere excluded. (C) Statisti
the mean of triplicate wells. Data are shown as means + SDs (*p b 0.05). (D), (E) Colony-for
OP9-Lhx2/ESCs and OP9-GFP/ESCs co-culture formed CFU-GM, CFU-M and BFU-E colonies.of the cytokine mSCF (Fig. S1D). Thus, we successfully overexpressed
functional Lhx2 in OP9 cells.
To investigate whether the OP9-Lhx2 line could promote the hema-
topoietic differentiation of PSCs, we ﬁrst carried out an in vitro OP9-
Lhx2/PSCs co-culture assay (Fig. 1A). Five million PSCs (H1) were seed-
ed onto an OP9 monolayer in a 100 mm culture dish. The mixed cells
were cultured in differentiation medium consisting of α-MEMmedium
supplemented with 10% deﬁned fetal bovine serum (Hyclone) and
monothioglycerol (100 μmol). After 9 days of co-culture, CD34+ cells
were enriched with immunomagnetic beads and re-plated onto an
OP9monolayer for a second round of co-culture in differentiationmedi-
um supplemented with 20 ng/ml BMP4, 50 ng/ml SCF, 20 ng/ml TPO,atopoietic differentiation by ESC (H1 line)/stromal cell co-culture. (B) Phenotypic identi-
cal analysis of hematopoietic cells derived from co-culture system. Each column represents
ming assay of CD34+ cells derived from co-culture. The hematopoietic progenitors from
398 X. Chen et al. / Stem Cell Research 15 (2015) 395–40220 ng/ml IL-3, 20 ng/ml IL-6, and 50 ng/ml Flt3-L. Round and bright
blood cells began to become evident at day 15, and they were robust
by day 18. To identify the hematopoietic cells, we analyzed the pheno-
types of hematopoietic cells using ﬂow cytometry. Consistent with our
hypothesis, OP9-Lhx2/PSCs co-culture produced signiﬁcantly more he-
matopoietic progenitors (CD45+CD34+) and mature blood cells
(CD45+CD34−) than the counterparts derived from OP9/PSCs co-
culture (Fig. 1B, C). We further performed a colony-forming-unit assay
to evaluate the function of hematopoietic progenitors derived from
our co-culture system. Both hematopoietic progenitors derived from
OP9-Lhx2/PSCs and OP9/PSCs yielded multiple colony types, includingFig. 2.OP9-Lhx2 facilitates derivation of murine hematopoietic progenitors in vivo via teratoma
(B) OP9-Lhx2/ESCs (C57/B6 background, CD45.2+)-formed teratomas produced a higher pro
Teratoma-derived blood cells were deﬁned as tdTomato+CD45.2+ cells; teratoma derived he
show the analysis of representative teratomas of two groups. (C) Statistic analysis of phenoty
Data are shown asmean+SD (*p b 0.01). (D)Hematopoietic progenitors derived fromOP9-Lhx
(tdTomato+CD45.2+CD48−CD150+) were transplanted into each lethally irradiated recipient
blood (PB) detected a low engraftment of OP9-Lhx2/mESCs teratoma-derived hematopoietic ce
cells in peripheral blood in recipients (n = 3) one month after transplantation.CFU-GM, CFU-M and BFU-E (Fig. 1D, E). Thus, OP9-Lhx2/PSCs co-
culture efﬁciently produced multipotent hematopoietic progenitors.
3.2. OP9-Lhx2 facilitates the derivation of murine and human hematopoietic
progenitors in vivo via teratoma formation
To investigate the ability of theOP9-Lhx2 line to facilitate the deriva-
tion of murine hematopoietic progenitors with engraftment potential,
we used a teratoma formation model to produce hematopoietic cells in
a 3-D in vivo microenvironment (Fig. 2A). We ﬁrst co-injected one mil-
lion OP9-Lhx2 cells with onemillionmouse PSCs (tdTomato+CD45.2+)formation. (A) Strategy for producing hematopoietic cells in vivo via teratoma formation.
portion of hematopoietic progenitors compared with OP9-GFP/ESCs teratoma controls.
matopoietic progenitors were deﬁned as tdTomato+CD45.2+CD150+CD48− cells. Plots
pic HSCs. Teratomas from three teratoma-bearing mice from each group were analyzed.
2/mESCs teratoma are transiently transplantable. Five hundred hematopoietic progenitors
(CD45.1+) via an injection into the femur cavity. A ﬂow cytometric analysis of peripheral
lls (CD45.2+CD45.1−) four weeks after transplantation. (E) Lineages analysis of engrafted
Fig. 3. OP9-Lhx2 facilitates the derivation of human hematopoietic progenitors in vivo via teratoma formation. (A) Flow cytometry analysis of human hematopoietic progenitors derived
from OP9/hESCs and OP9-Lhx2/hESCs teratomas. An analysis was conducted 8–10 weeks after ESC injection. Human hematopoietic progenitors were phenotypically deﬁned asmCD45−
hCD45+hCD34+hCD38− cells. Representative plots show the gating strategy of teratoma-derived live blood cells. (B) Frequencies of hCD45+ cells in teratomas. Single live cells prepared
from teratomas (n = 3) were analyzed. (C) Statistic analysis of hematopoietic cells derived from three representative teratomas of each group in the same batch experiments. Data are
shown as means + SDs (*p b 0.05). (D) Human teratoma-derived hematopoietic progenitors gave rise to colonies in the CFU assay. Flow cytometry analysis conﬁrmed that the cells
from CFU colonies were human blood cells. Colonies were selected and mixed with 0.25 million mouse bone marrow cells (mCD45+) to protect the few human cells (hCD45+).
(E) PCR conﬁrmed the human origin of CFU colonies. Four representative colonies from the CFU assay were picked up. Then cDNAs of individual colonies were used for PCR to detect
human CD45 gene.
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were separated from the teratoma-bearing mice. To assess the produc-
tion of hematopoietic progenitors, we analyzed the single live cells de-
rived from teratomas by ﬂow cytometry (Fig. 2B). To deplete mouse
blood contaminants from teratoma-bearing mice, we ﬁrst gated out
tdTomato-negative cells. Teratoma derived hematopoietic cells were fur-
ther deﬁned as tdTomato+CD45.2+ cells. We further combined CD150
and CD48 surface markers to deﬁne the HSC-enriched population
(CD150+CD48−). Interestingly, teratomas from OP9-Lhx2/PSCs pro-
duced much more hematopoietic progenitors than teratomas from
OP9/PSCs (Fig. 2C). To verify the engraftment potential of hematopoietic
cells derived from teratoma formation, CD150+CD48− progenitor cells
were sorted from teratomas and transplanted into lethally irradiated
mice. One month after transplantation, the peripheral blood of each re-
cipient was analyzed for engraftment. Hematopoietic progenitors from
some OP9-Lhx2/PSCs teratomas showed low levels of engraftment in
the peripheral blood (Fig. 2D). However, hematopoietic progenitors
from OP9/PSCs teratomas (0/20) showed no engraftment. On average,
hematopoietic progenitors from 15% OP9-Lhx2/PSCs teratomas showed
transient engraftment potential, but none produced long-term
engraftable blood cells. A further phenotypic analysis indicated that he-
matopoietic progenitors from OP9-Lhx2/PSCs teratomas reconstituted
myeloid and B lymphoid lineages but lacked T cells (Fig. 2E).
To investigate whether OP9-Lhx2 also enhances human hematopoi-
etic differentiation in vivo, we analyzed hematopoiesis in OP9-Lhx2/
hPSCs teratoma formation. Four million human PSCs and one million
OP9-Lhx2 or OP9 control cells were co-injected into the inguen of
NOD-SCID mice. Seven to nine weeks after co-injection, single cells
were prepared from the teratomas for ﬂow cytometry analysis. ToTable 1
Differentially expressed genes in OP9-Lhx2 versus OP9-GFP control cells.
Gene
symbol
GenBank
accession
Log2 fold
change
Tnn NM_177839 Inf
Megf10 NM_001001979 4.76
Nrp2 NM_002077403 4.04
Sorcs2 NM_030889 3.00
Cdh2 NM_007664 1.92
Adam8 NM_001291066 1.88
Tfrc NM_011638 1.66
Apln NM_013912 1.50
Procr NM_011171 1.44
Sema5a NM_009154 1.40
Met NM_008591 1.34
Adnp NM_009628 1.27
Emp2 NM_007929 1.17
Ctsl NM_009984 1.11
Mrc2 NM_008626 −1.15
Bmp1 NM_009755 −1.18
Fgfr2 NM_010207 −1.24
Thbs1 NM_011580 −1.27
Itgfb3 NM_016780 −1.33
Vcam1 NM_011693 −1.35
Lrp6 NM_008514 −1.59
Thbs2 NM_011581 −1.68
Jag1 NM_013822 −1.81
Notch3 NM_008716 −2.34
Ctsh NM_007801 −2.60
Slc1a3 NM_148938 −2.82
Sned1 NM_172463 −2.86
Hs6st2 NM_001077202 −2.89
Npr3 NM_001039181 −3.03
Chst15 NM_029935 −3.61
Clec2d NM_053109 −3.64
Mest NM_001252292 −4.54
Itga11 NM_176922 −5.12
Epha4 NM_007936 −6.09
Aoc3 NM_009675 −6.21exclude mouse blood cell contaminants, we ﬁrst gated out mCD45.1+
cells. We then used cord blood white cells as a positive control to gate
the human CD45+ cells in teratoma single cells. Human blood cells
from teratoma were further deﬁned as hCD45+mCD45−mTER-119−
cells. To assess whether OP9-Lhx2/hPSCs teratomas produce a higher
proportion of human hematopoietic progenitors, we combined the lin-
eage marker CD38 and hematopoietic stem/progenitor marker CD34
in subsequent analyses. Signiﬁcantly more hematopoietic progenitors
(CD38−CD34+) were derived from OP9-Lhx2/hPSCs teratomas com-
pared with the counterparts derived from the OP9/hPSCs control
(Fig. 3A-C). To further evaluate the function of human hematopoietic
progenitors derived from teratoma hematopoiesis, we sorted the
CD34+CD38− cells and carried out a CFU assay. CFU colonies were evi-
dent in the culture dish ten to fourteen days after plating (Fig. 3D).
Because human progenitors were rare in teratoma hematopoiesis
(~10,000 CD34+ cells per teratoma), we attempted to exclude the pos-
sibility that these CFU colonies are contaminants of murine blood cells
that arise during the long-term sorting of billions of cells for each tera-
toma. We selected the cells from each colony and combined them
with 0.25millionmouse CD45.1 protector cells for ﬂow cytometry anal-
ysis. A population of human blood cells (mCD45.1−hCD45+) was clear-
ly evident (Fig. 3D). To further conﬁrm the human origin of these
colonies, we performed PCR and successfully detected the human
CD45 gene using the cDNAs from the picked colonies (Fig. 3E). To inves-
tigate the niche of teratomahematopoiesis, we also performedmorpho-
logic examination of teratomas sections. Hematoxylin/Eosin staining
demonstrated that blood cells were identiﬁed in a bone-marrow-like
niche surrounded by cartilage (Fig. S2). However, we failed to detect
engrafted human blood cells when we transplanted the CD34+CD38−p-value Biological process
2E-75 Cell-matrix adhesion/cell growth and migration
5E-61 Cell proliferation/cell differentiation
6E-80 Angiogenesis/negative chemotaxis
5E-36 Transport
7E-36 Signal transduction/cell adhesion and migration
6E-11 T cell differentiation in thymus/cell adhesion
5E-39 Osteoclast differentiation/bone resorption
8E-17 Signal transduction/cell proliferation
2E-12 Antigen processing and presentation/blood Coagulation
9E-09 Cell chemotaxis/endothelial cell proliferation
4E-26 Phosphorylation/cell migration
0.007 Activation of protein kinase/transcription
2E-11 Signaling pathway/cell-matrix adhesion
4E-29 Cell communication/protein processing
2E-25 Collagen catabolic/osteoblast differentiation
7E-16 Cell differentiation/proteolysis
7E-08 Angiogenesis/bone development
2E-23 Cell adhesion/part of the HSC niche
4E-10 Cell adhesion/signaling pathway
4E-15 Cell adhesion/T cell proliferation
2E-12 Wnt-activated receptor activity/protein binding
3E-70 Cell adhesion/angiogenesis
7E-25 Notch signaling/T cell mediated immunity
4E-41 Notch signaling pathway/cell differentiation
2E-22 Cell proliferation/apoptotic signaling pathway
3E-16 Metabolic process/neuron differentiation
5E-109 Cell-matrix adhesion
5E-137 Transferase activity
4E-25 Signaling pathway/osteoclast proliferation
8E-27 Hexose biosynthetic process
2E-24 Osteoclast differentiation/signal transduction
6E-86 Regulation of lipid storage
2E-72 Cell adhesion/signaling pathway
3E-54 Cell adhesion/signaling pathway
5E-59 Leukocyte migration/cell adhesion
401X. Chen et al. / Stem Cell Research 15 (2015) 395–402cells into immune-deﬁcient mice (data not shown). Thus, OP9-Lhx2
facilitated the derivation of murine/human hematopoietic progenitors
in vivo via teratoma hematopoiesis.
3.3. OP9-Lhx2 enhances hematopoietic fate partially via the upregulation of
Apln
To investigate the underlying molecular effectors that facilitate he-
matopoietic differentiation by OP9-Lhx2, we carried out RNA-seq to
obtain the gene expression proﬁle of OP9-Lhx2 and OP9-GFP control
cells. Considering the niche cell effect of OP9-Lhx2on hematopoietic dif-
ferentiation, we focused on secreted proteins and membrane proteins
(SP/MP) that were upregulated or downregulated by Lhx2 in OP9
cells. TheGOanalysis of theRNA-seq data demonstrated that the ectopic
expression of Lhx2 in OP9 upregulated 14 SP/MP and downregulated 21
SP/MP genes (Table 1). A quantitative RT-PCR assay further conﬁrmed
the differential expression of these genes (Fig. S3).
To identify the key effectors of Lhx2 that improve the efﬁciency of
hematopoietic induction, we ﬁrst searched the literature for the 35 dif-
ferentially expressed SP/MP genes. Notably, Apln has been reported to
promote the hematopoietic differentiation of human embryonic stem
cells (Yu et al., 2012). We then evaluated whether the enforced expres-
sion of Apln in OP9 cells could enhance hematopoietic differentiation.
Apln cDNA was inserted into the same vector to overexpress the Lhx2
gene. An OP9-Apln cell line was established via the retroviral transduc-
tion of the Apln gene into OP9 cells (Fig. 4A). We then used a OP9-Apln/
PSCs co-culture to assess the production of hematopoietic cells. As ex-
pected, OP9-Apln increased the ratio of CD34 positive hematopoieticFig. 4. Enforced expression of Apln in OP9 cells promotes generation of ESCs-derived hematopoi
(B) Statistical analysis of hematopoietic cells derived from OP9-GFP/ESCs and OP9-Apln/ESCs co
assay of CD34+ cells derived from OP9-Apln/ESC co-culture. The hematopoietic progenitors froprogenitors compared with the effect observed for the OP9/PSCs co-
culture control (Fig. 4B). To conﬁrm the functions of CD34+ cells de-
rived from OP9-Apln/ESC co-culture, we performed CFU assays. Our re-
sults conﬁrmed that CD34+ cells formed CFU-GM, CFU-G and BFU-E
colonies (Fig. 4C, D). Thus, OP9-Lhx2 enhanced hematopoietic fate in
part via the upregulation of Apln.
4. Discussion
The generation of induced HSCs from PSCs is an ideal approach for
overcoming the lack of suitable HSC resources and graft rejection. At-
tempts to derive robustly induced HSCs from PSCs in recent decades
failed due to multiple bottlenecks, including limited approaches for
identifying and manipulating the stemness of HSCs in vitro (Shepard
and Talib, 2014). In this study, we established a niche cell line,
OP9-Lhx2 that can promote hematopoietic derivation using in vitro
co-culture and in vivo teratoma formation methods. Interestingly, the
ability of OP9-Lhx2 to facilitate the production of hematopoietic progen-
itors from PSCs is conserved frommurine to human PSCs. Previous mod-
iﬁcations of OP9 cells directly focused on extrinsic factors that play roles
in hematopoietic development (Holmes and Zuniga-Pﬂucker, 2009;
Ichii et al., 2012). In this study, we developed a new approach and
showed that the ectopic expression of transcription factors in OP9 cells
can also improve the niche to produce hematopoietic progenitors from
PSCs. A mechanistic analysis demonstrated that OP9-Lhx2 promotes
hematopoietic derivation partially via the upregulation of Apln, which
has been reported to enhance the hematopoietic speciﬁcation of PSCs
in vitro (Yu et al., 2012). Because Lhx2 regulated the expression level ofetic cells. (A) Quantitative PCR of Apln expression level in OP9-GFP/OP9-Apln stromal cells.
-culture. Data are shown as means + SDs (*p b 0.05, **p b 0.01). (C), (D) Colony-forming
m OP9-Apln/ESCs formed CFU-GM, CFU-M and BFU-E colonies.
402 X. Chen et al. / Stem Cell Research 15 (2015) 395–402several genes involved in cell adhesion/signaling pathways, additional
effectors might also enhance the hematopoietic speciﬁcation by OP9-
Lhx2.
Induced HSCs were derived from both mouse and human PSCs via
intra-teratoma hematopoiesis, which provides a new tool for investigat-
ing the extrinsic and intrinsic factors of hematopoietic development
(Amabile et al., 2013; Suzuki et al., 2013).We used this approach to con-
ﬁrm that OP9-Lhx2 promotes the production of bothmouse and human
hematopoietic progenitors in vivo. The derived hematopoietic progeni-
tors engrafted and reconstitutedmyeloid and B lymphoid lineages in re-
cipients, but they lacked the potential for T lymphopoiesis. We tested
multiple ESC and iPSC lines and excluded the possibility that the defect
in the T potential was due to defects in the individual PSC line. Hemato-
poietic progenitors derived from PSCs have been reported to possess a
homing defect. This possibilitywas excluded in our experiment because
engraftments via the intra-medullary tibia injection of teratoma-
derived hematopoietic progenitors failed. Hematopoietic progenitors
were also detected in the bone marrow of teratoma-bearing mice, but
the transplantation of these cells into myeloablated mice again failed
to show engraftments. Thus, the hematopoietic progenitors derived
from teratoma hematopoiesis in our experiment possessed intrinsic de-
fects and could not self-renew in the long term. In our experimental set-
tings, even the hematopoietic progenitors from individual teratomas
showed transient engraftment only in a low ratio of the recipients,
which indicated functional variations of hematopoetic cells derived
from teratoma hematopoiesis. We detected human blood cells from
bulk teratoma cells using FACS analysis and PCR of CFU cells, however,
blood cells surrounded by bone-marrow-like niche in teratomas in our
experiments are extremely rare, and the identity of human blood cells
origin must be further evaluated by situ staining using human CD45
antibodies. In fact, the very limited 0.1%–2% hematopoietic chimerism
in the bone marrow with predominant myeloid engraftment in as few
as 4% recipients demonstrated that the teratoma hematopoiesis tool
must be optimized further (Slukvin, 2013; Amabile et al., 2013; Suzuki
et al., 2013).
In conclusion, OP9-Lhx2 cells provide a better niche for the produc-
tion of hematopoietic progenitors from PSCs, partially via the upregula-
tion of Apln. OP9-Lhx2 might be used as a new tool for hematopoietic
derivation both in vitro and in vivo. Our strategy might also be used to
build additional niche cell lines by screening additional transcription
factors that play important roles in hematopoietic development in a
cell non-autonomous manner.
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